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Abstract: Eyelashes hypotrichosis is a condition indicated by an inadequate amount of 
  eyelashes. Hypertrichosis of eyelashes, characterized by excessive eyelash growth, is a regular 
phenomenon associated with ophthalmic prostaglandin and prostamide analogs. Recently, the 
US Food and Drug Administration approved Latisse® (bimatoprost 0.03% solution), identical 
to the ophthalmic solution for glaucoma treatment, for increasing eyelash length, thickness and 
darkness in patients with hypotrichosis of the eyelashes. When prostaglandin and prostamide 
analogs interact with the prostanoid receptors in the hair follicle, this most likely stimulates 
the resting follicles (telogen phase) to growing follicles (anagen phase). Prostaglandin and 
  prostamide analogs may also prolong the anagen phase of eyelashes, leading to an increase of 
eyelash length. Although bimatoprost is effective in promoting increased growth of healthy 
eyelashes and adnexal hairs, its effectiveness in patients with eyelash alopecia areata is debatable 
and its protective effect is not yet studied in patients with eyelash loss secondary to radiation or 
chemotherapy. Bimatoprost is generally safe when applied to the base of the eyelashes at the lid 
margin with minimum side effects. However, other ocular or systemic side effects associated 
with ophthalmic prostaglandin and prostamide analogs may occur when instilled on the surface 
of the eye, and patients must be informed and monitored.
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Introduction
Hypotrichosis is characterized by a less than normal amount of hair, and eyelashes 
hypotrichosis is the term for an inadequate amount of eyelashes. Eyelashes provide 
a natural protective barrier for the eyes from sunshine, wind, foreign bodies, and 
  perspiration. They perform a similar function to the whiskers on a cat or a mouse. 
They are sensitive to the touch and provide a warning when an object is near the eye, 
which in turn prompts the eye to close reflexively.1
In addition to the protective purpose of the eyelash, a more contemporary goal for 
eyelash length and thickness in modern humans is cosmetic attraction. Eyelashes frame 
the eyes together with the eyebrows, hairline, cheekbones, nose, lips and chin to create a 
facial appearance that is unique to every individual. The absence of eyelashes removes 
one of the salient anatomical features associated with a normal facial appearance.1 Long 
eyelashes are also considered a sign of femininity and beauty in most if not all cultures.
Causes of eyelashes hypotrichosis are many, including hereditary, aging, 
  chemotherapy, other medical treatment and unknown causes. Physical trauma 
  involving the face, eye surgery and trichotillomania may also cause thin or absent 
lash growth.2,3Clinical Ophthalmology 2010:4
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Since the introduction of latanoprost in 1996 as an 
ocular hypotensive agent for the treatment of glaucoma, 
  hypertrichosis of eyelashes has been reported as a regular 
phenomenon associated with ophthalmic prostaglandin and 
prostamide analogs.4,5 When compared to latanoprost in 
  clinical study, ophthalmic bimatoprost 0.03% was found 
to have an even higher occurrence of eyelash growth.6–9 
Recently, Latisse® (Allergan Inc. Irvine, CA) which is 
bimatoprost 0.03% solution and identical to the ophthalmic 
solution for glaucoma treatment, was approved by the US 
Food and Drug Administration (FDA) for increasing eyelash 
length, thickness and darkness in patients with hypotrichosis 
of the eyelashes. In this article, bimatoprost is reviewed 
in terms of its pharmacology, efficacy, and safety in the 
treatment of eyelash hypotrichosis. Although this review 
primarily focuses on bimatoprost, it is necessary to discuss 
the effects of other prostaglandin analogs on eyelashes, 
particularly latanoprost, which has been more extensively 
studied in hypertrichosis of eyelashes. Latanoprost and 
bimatoprost also share many similarities both structurally 
and pharmacologically.
Pharmacology
Human eyelash characteristics
Human have 90 to 160 eyelashes in the upper eyelid and 75 
to 80 in the lower eyelid, with great variation of length.10,11 
The lashes typically originate from the anterior lamella of 
the eyelid where they lie on the tarsal plate. They grow in 
imperfect rows of 5 to 6 in the upper lid and 3 to 4 in the 
lower lid in Caucasians.12,13 An eyelash is terminal hair, which 
is coarse, medullated, long and pigmented. In comparison, 
vellus hair, which is often found on a woman’s face, is soft, 
unmedullated, short and non-pigmented. Eyelashes have the 
widest diameter of body hairs and are the most pigmented 
of the terminal hairs.14
Hair follicles have a unique cyclical behavior pattern and 
the entire cycle varies in duration depending on the location 
in the body. Each human eyelash lives an average of 3 to 
6 months.13,15 The growth phase (anagen) of the eyelash hair 
  follicle and eyelash lasts for approximately 30 days. At the end 
of the eyelash growth period, a brief transition stage (catagen) 
of 15 days follows, with shortening of the hair follicle. 
Finally, the follicle enters a resting phase (telogen) of about 
100 days, leading to the detachment of the eyelash.10,13,16–18 
The proportion of follicles in telogen is normally higher in 
eyelashes than scalp hairs. One study estimated 59% to 85% 
of eyelash follicles are in telogen phase, depending on whether 
they are on the upper or lower lid.18
The length of an eyelash can vary greatly, from 8 to 
12 mm in the upper lid and from 6 to 8 mm in the lower lid, 
and depends on the ethnicity of the individual.10,11 Eyelash 
follicle growth rate is also quite variable, with an average of 
0.12 to 0.14 mm daily.11,13 All eyelashes are characterized by 
a tendency to bend from the bulb to the top of the shaft.13 The 
degree of curvature depends on ethnic origin.11 Interestingly, 
eyelashes do not turn grey with aging, or only at a very late 
stage.10
Several factors are involved with hair follicle growth 
and cycling but their effects on eyelash growth are unclear. 
Androgens are the principal hormones that control sexual 
hair growth by receptors localized in the dermal papilla, but 
eyelashes do not seem to be as sensitive.19,20 Retinoic acid 
derivatives affect the hair growth cycle in mice by increasing 
the length of the anagen phase, and insulin-like growth factor-
I slows the hair cycle entry in the catagen phase. Growth 
hormone, insulin, glycocorticoids, and prolactin are also 
implicated, but there is no evidence to support an involvement 
of these hormones in eyelash growth.17
Prostamides metabolism
Bimatoprost is a synthetic product initially designed 
  pharmacologically to reduce the intraocular pressure (IOP) 
for the treatment of glaucoma. It is structurally similar 
to the other prostaglandin F2α (PGF2α) analogs, includ-
ing latanoprost, travoprost and unoprostone, but has an 
ethyl amide instead of an isopropyl ester at the C-1 car-
bon of the alpha chain. Bimatoprost has been proposed 
to be similar to a class of naturally occurring fatty acid 
amides otherwise known as “prostamides” (prostaglandin 
  ethanolamides).21,22
Prostamides are recently identified as a unique 
class of compounds that are formed from anandamide 
catalyzed by cyclooxygenase-2 (COX-2). Anandamide 
is one of the naturally occurring mammalian endogenous 
cannabis-like ligands (endocannabinoids) derived from 
arachidonic acid.
The biosynthesis of anandamide consists of two steps of 
enzymatic reactions: (1) formation of the membrane glyceropho-
spholipid precursor,  N-arachidonoylphospharidylethanolamide 
(NArPE), by the transfer of a fatty acyl chain from the sn-1 
position of glycerophospholipids to the amino group of pho
sphatidylethanolamine, (2) enzymatic hydrolysis of NArPE 
catalyzed by a N-acylphophatidylethanolamides selec-
tive phospholipase D (NAPE-PLD) to form anandamide.23 
After synthesis, anandamide is rapidly inactivated via a 
tightly controlled series of events involving sequestration Clinical Ophthalmology 2010:4
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by cells and enzymatic hydrolysis of its amide bond to 
  arachidonic acid and ethanolamide.24 With the presence of an 
  arachidonate moiety in their chemical structure, anandamide 
and another endocannabinoid, 2-arachidonoylglycerol 
(2-AG) are substrates for enzymes of the arachidonate 
casade including COX-2, but not COX-1.25 Similar to the 
conversion of arachidonic acids to prostaglandins by COX 
and prostaglandins synthase, COX-2 converts anandamide 
to the endoperoxide intermediates prostamide G2 (PMG2) 
and prostamide H2 (PMH2), which are then converted by 
  specific prostaglandins synthases to the various prostamides.26 
However, unlike anandamide, prostamides do not possess 
cannabimimetic and related activity, and their physiological 
actions have not been fully investigated.
Synthetic prostamide analog, bimatoprost, and 
  prostaglandin F2α analogs, such as latanoprost, travoprost 
and unoprostone are effective ocular hypotensive agents. 
The mechanism of IOP reduction involves secretion of 
  metalloproteinases by ciliary smooth muscle cells and 
  remodeling of the extracellular matrix, the resulting 
  widening of intermuscular spaces, and ultimately an 
increase of uveoscleral outflow of aqueous. Although 
  prostamides are structurally similar to prostaglandins, they 
exhibit no meaningful activity at prostanoid receptors.26 
Experimental evidence suggests that prostamides may act 
as endogenous ligands at their own receptors (prostamide 
  receptors). Nevertheless, prostamide activity has not 
been demonstrated in the absence of prostanoid receptor 
  activity.26
In a recent study, Liang at al identified 6 splicing 
  variants of prostanoid FP receptor mRNA in human ocular 
tissues.27 Immunoprecipitation analysis further confirmed 
that the FP receptor is dimerized with FP receptor variant-4 
(altFP4). It appears that the FP-altFP4 heterodimer maintains 
  responsiveness to PGF2α and its analogs and acquires 
  sensitivity to bimatoprost. It was also found that PGF2α and 
bimatoprost has a different calcium mobilization profile. 
PGF2α elicited a rapid increase in intracellular calcium 
  followed by a steady state phase. In contrast, bimatoprost 
elicited an immediate increase in intracellular calcium 
  followed by a second phase, and the prostamide antagonist, 
AGN211335, selectively and dose-dependently inhibited 
the bimatoprost-initiated second phase, but did not block 
the action of PGF2α. Novel ligand-recognition sites may 
have emerged as a result of prostanoid-prostanoid receptor 
hererodimerization, and FP-altFP complexes may represent 
the underlying basis of bimatoprost pharmacology on IOP.27 
It remains to be proven if this receptor heterodimerization 
is also responsible for the action of bimatoprost on eyelash 
growth.
Hair growth induced by prostaglandins 
and prostamides
Prostaglandins are probably involved in a specific and 
complex network in hair growth and differentiation control. 
Most of the hair cell types are endowed with prostaglandin 
metabolism machinery and are able to produce PGE2 
and/or PGF2α; and all prostaglandin receptors are pres-
ent in hair follicle.28–30 The epithelial part of the hair bulb 
was identified by immunohistology and enzyme-linked 
  immunosorbent assays as the main source of prostaglandin 
synthesis and interconversion.28 Both the F series and 
E series prostaglandins may have an effect on hair growth.31 
Inhibitors of prostaglandin endoperoxide synthase such 
as indomathacin, ibuprofen, and aspirin were shown to 
block prostaglandin synthesis and inhibit hair growth.32,33 
  Minoxidil, a known hair growth agent, was reported to 
activate activity of purified COX-1, suggesting a positive 
role of prostaglandin in hair growth onset.34 Latanoprost, 
a PGF2α analog, was found to be able to promote hair 
regrowth in C57/B16 mouse model.35 PGF2α and PGE2 were 
reported to have hypertrichotic effects on mice.36 PGF2α 
and prostaglandin F receptor analogs were able to induce 
telogen to anagen transition. Similar effects were found on 
stump-tailed macaque.37
Although prostaglandin metabolism machinery and 
  prostaglandin receptors are present in hair follicle, the 
mechanisms by which prostaglandins and prostamides 
trigger eyelash growth are not clear. So far, this area of 
research is limited to prostaglandin analogs, or specifically, 
latanoprost. It is suggested that hypertrichosis following 
administration of prostaglandin analogs is probably a result 
of the induction of the anagen phase in telogen phase follicles 
of eyelashes.15 Prostaglandin analogs may also prolong 
the anagen phase of eyelashes, leading to an increase of 
eyelash length.38 The increased anagen duration has been 
hypothesized to be determined at the initiation of the anagen 
phase and is probably controlled by the dermal papilla.39 In 
a study to determine the minimum interval of latanoprost 
exposure necessary to cause hypertrichosis of eyelashes, 
brief exposure to latanoprost (22 days) was associated 
with hypertrichosis similar to those following sustained 
exposure. The effect persisted to some degree throughout 
the duration of a follow-up interval of 14 months.15 The 
author suggested that a program is initiated to trigger the 
anagen phase of the hair cycle in the follicles of eyelashes Clinical Ophthalmology 2010:4
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and that this program is able to proceed in the absence of 
an ongoing stimulus.15
Efficacy
Hair growth associated with 
prostaglandin and prostamide analogs
Increase of hair growth is regularly associated with ophthalmic 
application of different prostaglandin and prostamide analogs 
in patients of different ethnicities and age groups. In a series 
of 317 patients, Demitsu et al reported latanoprost-induced 
hypertrichosis in 77% of patients.40 In Japanese patients 
receiving ophthalmic latanoprost treatment for its ocular 
hypotensive effect, increased vellus hair of the lid was 
noted in 37.6% and hypertrichosis of eyelashes was noted 
in 50.5% of patients.41 In a study to compare the eyelash 
  lengthening effect of latanoprost in adults and children 
with glaucoma, Elgin et al found that the mean difference 
in eyelash lengths at baseline and the sixth month was 
0.67 ± 0.09 mm in adults and 0.75 ± 0.25 mm in children.42 
After taking travoprost 0.004% for 12 months, changes in 
eyelashes, including increased length, thickness, density, and 
color, were reported in 57% of patients.43 Eyelash growth has 
been reported in 12.6% to 35.7% of patients during clinical 
trials of bimatoprost 0.03%.6,44,45
In a 3-month bimatoprost versus latanoprost trial, eyelash 
growth was more common in the bimatoprost group (13% 
bimatoprost vs. 4% latanoprost).6 Hypertrichosis appears 
to occur earlier during bimatoprost treatment as compared 
to latanoprost. This may be because of the possibility 
that bimatoprost, unlike latanoprost, does not need to be 
  converted into an active metabolite in order to extend potent 
  pharmacological activity. Another possible explanation is that 
bimatoprost sensitivity may be conferred by interacting with 
FP-altFP heterodimer receptor instead, and the additional 
secondary calcium signaling pathway elicited by bimatoprost 
may translate into a stronger response of hair growth.
Bimatoprost seems to be able to increase the length of the 
eyelash more than latanoprost. In an unpublished randomized 
vehicle-controlled, multicenter, clinical trial, 278 patients 
were assigned to apply either one drop of bimatoprost 
(n = 137) or vehicle only (n = 141) to the upper eyelid margin 
at the base of the eyelashes once nightly for 16 weeks.46 
Eyelash prominence, measured primarily by length but also 
by thickness and darkness, was rated using a 4-point Global 
Eyelash Assessment scale developed by the manufacturer. An 
increase in the scale occurred in 78% (1 grade) and 32.8% 
(2 grades) on bimatoprost compared to 18% and 1.4% in the 
vehicle group, respectively. In the bimatoprost group, eyelash 
length increased an average of 1.4 mm (25%) compared to 
0.1 mm (2%) in the vehicle group after 16 weeks of treat-
ment.46 In a prospective study assessing the effect of eyelash 
growth in the ipsilateral eyelids of patients treated with 
unilateral ophthalmic latanoprost for glaucoma, Johnstone 
documented an average increase of 19.5% in eyelash length 
with mean treatment duration of 20 weeks.4
The FDA has approved bimatoprost in a 0.03% solution 
for increasing eyelash length, thickness and darkness in 
patients with hypotrichosis of the eyelashes. For eyelash 
enhancement, one drop of bimatoprost 0.03% solution is 
placed on a single-use applicator and applied to the upper 
eyelid margin along the roots of the eyelashes once nightly; 
a new applicator should be used for each eye.
Characteristics of eyelashes  
in the presence of prostaglandin  
and prostamide analogs
Hypertrichosis is a regular seen side effect in eyes treated 
with ophthalmic prostaglandin and prostamide analogs. In 
a prospective study of 43 patients who were unilaterally 
treated with latanoprost, researchers identified a number 
of characteristics of eyelashes treated with latanoprost.4 
After treatment, eyelashes increased in length, thickness, 
and pigmentation. The number of eyelashes also increased 
in preexisting lash rows and in areas of transition between 
the terminal lashes along the lash line and the vellus hairs 
of the skin. These hairs had a more robust appearance, were 
longer, thicker, and more heavily pigmented, and arose at a 
more acute angle from the skin than in the control eye. The 
vellus and intermediate hairs had transformed into terminal 
hairs, and produced the appearance of new rows of terminal 
  eyelashes in the lid margin. The changes in the appearance 
of the eyelashes were not limited to the lashes along the 
lid margin, but also affected the hairs in the medical and 
lateral canthal areas.4 It is reasonable to expect that all these 
changes may be more prominent and obvious in bimatoprost 
treatment. The clinically observable eyelashes hypertrichosis 
resolved following discontinuation of latanoprost or 
  bimatoprost.4,46
Even brief exposure to an ophthalmic prostaglandin analog 
appears to be associated with eyelash change. Johnstone 
reported that a very brief exposure to latanoprost could 
produce a similar effect of eyelash growth as compared 
to chronic exposure.15 However, the hypertrichosis had a 
marked irregular pattern of lash curling. The author postulated Clinical Ophthalmology 2010:4
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that the differences in appearance of eyelashes and pattern 
of eyelash growth between brief exposure and sustained 
  exposure to prostaglandin analogs may be secondary to a 
lack of uniform penetration into the hair follicle leading to 
asymmetric development of the follicle and inner root sheath. 
Some patients were also found to have persistent trichomegaly 
up to 14 months following a brief exposure to latanoprost.15 It 
is uncertain if similar characteristics of eyelash growth after 
brief exposure may happen to bimatoprost applied to upper 
eyelid margin along the roots of the eyelashes.
The hypertrichosis of eyelashes associated with 
  prostaglandin and prostamide analogs usually occurs together 
with darkening of the eyelashes. However, some patients 
developed bilateral poliosis after using different ophthalmic 
prostaglandin F2α analogs for treating primary open angle 
glaucoma.47
Eyelash regrowth in alopecia areata
There are case reports of the successful use of prostaglandin 
analogs including latanoprost and bimatoprost in the treatment 
of eyelash alopecia areata.48–51 In an 11-year-old patient who 
had alopecia areata with bilateral loss of eyelashes, Mehta et al 
reported a successful regrowth of the eyelashes after cutaneous 
treatment with latanoprost.51 Minimal lash growth was noted 
on all four lids 4 weeks after application of latanoprost once 
daily, and pronounced lash growth was noted in 8 weeks. 
Treatment was then altered to once a week and the number of 
eyelashes was maintained over the next 6 months.51
However, lack of efficacy of topical latanoprost and 
  bimatoprost ophthalmic solutions in promoting eyelash growth 
in patients with alopecia areata has also been reported.52 In a 
16-week, randomized, investigator masked, controlled study, 
11 patients with alopecia areata and greater than 50% bilateral 
eyelash loss were randomized to receive an application of 
either latanoprost or bimatoprost to the upper and lower eyelid 
margins of one eye only. No appreciable eyelash regrowth was 
noted on clinical assessment of eyelid margins or on review 
of digital photographs after 16 weeks. Authors questioned 
whether ocular instillation of prostaglandin analogs used in 
glaucoma treatment may be more effective in stimulating 
eyelash growth.52 In patients without eyelashes, it may be 
difficult to keep the cutaneously applied medication on the 
lid margin for adequate penetration into the hair follicles. It is 
also possible that irreparable damage to the follicle stem cells 
in some patients may have led to irreversible hair loss.
In another prospective study of similar design with 
bimatoprost 0.03% solution instilled on the eye, 7 patients 
(11 patients enrolled, 7 completed the study) with eyelash 
alopecia areata with greater than 50% bilateral eyelash 
loss received bimatoprost solution once daily to one eye, 
while the untreated eye served as the control.49 Bimatorpost 
was found to be ineffective in promoting eyelash growth 
in 5 patients with 95% or greater eyelash loss caused by 
alopecia areata. However, in 2 patients with 30% and 40% 
eyelashes present at baseline, some bilateral eyelash growth 
was noted.49 Another prostaglandin analog, travoprost, has 
also been studied in eyelash alopecia areata. Growth of 
  eyelashes was observed in only 1 out of 3 patients, whereas all 
three developed increased pigmentation of the eyelid skin.53 
It seems that prostaglandin or prostamide analogs are only 
effective in promoting eyelash regrowth in patients with a 
mild form of eyelash alopecia areata.
Eyelashes regrowth in other  
causes of hypotrichiasis
Prostaglandin analogs, not prostamide, have been studied 
in animal model of hair injury associated with radiation 
therapy and chemotherapy. Prostaglandin E2 (PGE2) analog 
was shown to have a significant degree of protection against 
  radiation-induced or doxorubicin-induced alopecia in 
mice.54–56 This protective effect has yet to be studied in human 
undergoing radiation therapy or chemotherapy.
Safety
Side effects of ophthalmic prostaglandin 
and prostamide analogs
Prostaglandin and prostamide analogs have been associated 
with similar systemic and local side effects when administered 
topically on the surface of the eye as an ocular hypotensive 
agent for glaucoma. When bimatoprost is applied to 
the eyelashes and lid margins in very close proximity to the 
surface of the eye to promote growth of the eyelash, potential 
side effects may occur if the medication is administered 
inappropriately on the surface of the eye.
Ophthalmic use of prostaglandin analogs and bimatoprost 
is known to be associated with increase iris pigmentation. 
Iris darkening may be due to increase of melanin granule 
size secondary to an induced heightened melanogenesis.57,58 
Older patients may have more iris color change when topical 
prostaglandin is used.59 Patients with hazel irises that have 
mixed coloring are at higher risk of iris darkening, whereas 
homogenous blue or brown irises have relatively little 
  likelihood of getting induced iris darkening.60
Conjunctival hyperemia is associated with ophthal-
mic prostaglandin analogs and bimatoprost. It is the most Clinical Ophthalmology 2010:4
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  common adverse event associated with bimatoprost 0.03% 
as ophthalmic therapy for glaucoma, which occurred in 42% 
to 46% of patients.6,44,45 Approximately 1% to 4% of patients 
discontinued treatment with bimatoprost 0.03% because of 
conjunctival hyperemia.44,45 Comparing with latanoprost, 
bimatoprost has significantly more conjunctival hyperemia 
and increased eyelash growth reported, but headaches were 
more commonly reported with latanoprost.6–8,61,62
Increase of pigmentation of the periocular skin is seen 
with ophthalmic prostaglandin analogs or bimatoprost 
therapy. The increase of pigmentation is caused by 
increased melanogenesis without melanocyte proliferation 
or inflammation.63 This side effect occurs more frequently 
with bimatoprost than latanoprost. Wiping the lid was found 
to help decrease the hyperpigmentation when a topical drop 
is used.64 Patients are advised to blot off any solution that 
drips from the treated area.
Deepening of the eyelid sulcus, periorbital fat atrophy, 
and relative enophthalmos have been reported with 
  ophthalmic travoprost and bimatoprost used in treatment of 
glaucoma.65–68 In some patients the disparity of periorbital 
appearance between the treated eye and the fellow eye 
returned to normal after discontinuation of the ophthalmic 
prostaglandin analogs or prostamide for a relatively long 
interval.66,68 The exact mechanism is uncertain, but fatty 
degeneration and reduced collagen fibers in the levator 
complex caused by the prostaglandin or prostamide analogs 
have been proposed as a possible mechanism.66,68
Anterior uveitis has been reported in patients using 
  ophthalmic prostaglandin or prostamide analogs.69,70 Anterior 
uveitis has been observed in approximately 1% of patients 
receiving latanoprost, which resolves with corticosteroid 
therapy.71 Association of latanoprost and uveitis has been 
confirmed with a dechallenge and rechallenge method in 
two studies.72,73 Because of the similar efficacy and safety 
profile between prostaglandin analogs and bimatoprost, 
use of these agents is generally avoided in eyes with active 
inflammation.
The association of herpetic simplex viral infection 
and prostaglandin analogs and bimatoprost has been 
  documented.74,75 Herpes simplex keratitis has been reported 
to develop after initiation of latanoprost therapy with 
  dechallenge and rechallenge method.76 In another case report, 
2 patients developed HSV dermatitis of the periocular skin 
after using latanoprost.77 Latanoprost has been shown to 
worsen acute herpetic keratitis in the rabbit eye (New Zealand 
white (NZW) rabbit) and increase the risk of recurrences 
in latently infected animals.78 However, in the Induced 
  Reactivation and Spontaneous Shedding HSV-1/NZW rabbit 
latency models, latanoprost was not found to promote ocular 
shedding of HSV-1.79 Use of any topical prostaglandin and 
prostamide analogs in patients with a history of ocular 
  herpetic viral infection should be avoided.
Patients with active or at risk of ocular inflammation or 
infection should avoid using bimatoprost to promote eyelash 
growth.
Specific safety concerns of bimatoprost 
used in treating hypotrichiasis
The most common local side effects reported by subjects in the 
clinical trial using bimatoprost as treatment of hypotrichosis 
were essentially consistent with those experienced by patients 
using bimatoprost as a treatment in glaucoma. The most 
common side effects in the clinical trial were eye pruritus, 
conjunctival hyperemia, eye irritation, dry eye symptoms, 
and erythema and hyperpigmentation of the eyelids.46
Although increase of the length, thickness and darkness of 
eyelashes are desirable effects of bimatoprost in treatment of 
hypotrichosis, excessive growth and thickness of the eyelashes 
has been reported after using the ophthalmic solution of 
bimatoprost 0.03% once daily after 1 to 3 months.80–82 
Patients were reported to have increased hair growth in the 
malar regions and external canthal area, excessive growth 
of eyelashes and eyebrows, and eyelid hyperpigmentation. 
In one patient, whose eyelash and eyebrow growth returned 
to normal within 2 months of stopping the ophthalmic 
  bimatoprost treatment, the medication was restarted with 
instruction to thoroughly clean the ophthalmic solution 
drippings from her eyes. Nevertheless, after one month of 
reinstating the treatment, excessive growth and thickness of 
the eyelashes and eyebrow was again observed along with 
malar hypertrichosis and eyelid hyperpigmentation.81 In 
addition, lash ptosis and trichiasis secondary to misdirected 
eyelash growth have also been reported in association with 
latanoprost and travoprost use.83,84
Ophthalmic bimatoprost 0.03% has been reported to 
cause changes in the pigmentation of tissues, including 
pigmentation of the periocular skin. Bimatoprost-induced 
periocular hyperpigmentation appears between 3 to 6 months, 
with hyperpigmentation resolving between 3 to 12 months 
upon discontinuation of the drug.85,86
Increased iris pigmentation has been cited as a side 
effect of ophthalmic bimatoprost when used in glaucoma 
treatment. However, iris pigmentation changes were not 
noted in the clinical trial of bimatoprost used for promoting 
eyelash growth. This is probably because the drug was Clinical Ophthalmology 2010:4
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applied at the lid margin and the root of the eyelashes and 
intraocular penetration was therefore minimized.46 Since 
iris pigmentation change, associated with use of ophthalmic 
  prostaglandin analog, can be permanent, patients who desire 
to use bimatoprost to promote eyelash growth must be 
informed of this possible side effect.
As mentioned above, there are patients reported to develop 
poliosis together with hypertrichosis when   ophthalmic 
  prostaglandin analog is used in treating glaucoma. Chen 
et al reported a series of 7 patients, aged 59 to 78, who 
developed poliosis after prostaglandin analogs were used; 
including 4 patients on latanoprost, 2 patients on bimatoprost, 
and 1 patient on travaprost. Poliosis was noted as earlier as 
6 weeks after starting treatment.47 The affected lashes were 
typically interspersed with normally pigmented lashes. The 
authors observed on several occasions that the white lashes 
were new, implying that the side effect may result from 
failure of pigmentation in newly stimulated eyelash growth 
or a stimulated growth of previously inconspicuous white 
lashes.47 A possible explanation proposed by the authors is 
that during the anagen phase of the hair follicle cell cycle, 
genetically predetermined differences in follicular response 
results in some dermal papillae secreting mitogens, whereas 
others synthesize inhibitory factors and result in varying 
response of hair follicles to prostaglandin analogs.15,47
The commercially available bimatoprost products (both 
Latisse® and Lumigan® [also marketed by Allergan Inc.]) 
  contain benzalkonium chloride as preservative. Ocular 
  exposure to benzalkonium chloride may have a cytotoxic 
effect on human cornea in some patients, and clinically 
present as erosion of epithelium, irritation, foreign body 
sensation, and other dry eye symptoms.87
Cystoid macular edema has been reported when 
  ophthalmic bimatoprost was used in high-risk patients 
(aphakia, pseudophakia with ruptured posterior capsule 
during surgery, history of uveitis, or retinal inflammatory 
or vascular disease). Cystoid macular edema developed in a 
patient with glaucoma therapy switched from latanoprost to 
bimatoprost 9 months after cataract surgery.88
Systemic side effects of bimatoprost
Systemic adverse events reported after treatment with 
  bimatoprost 0.03% have included symptoms of common cold 
and upper respiratory tract infection, headaches, abnormal 
liver function tests, asthenia and hirsutism. Bimatoprost 
0.03% did not have any clinically significant effect on heart 
rate or blood pressure in patients with glaucoma or ocular 
hypertension in clinical trials.45,89,90
Since bimatoprost is similar in structure and outcome with 
the other topical prostaglandin analogs, it is important to be 
aware of the side effects reported with the other prostaglandin 
analogs. There is a case report of abdominal cramps 
  associated with travoprost confirmed by dechallenge and 
rechallenge procedures.91 Other systemic events, each with 
an incidence of 1 or 2%, included chest pain/angina, muscle/
joint/back pain and rash/allergic skin reaction. Angina, 
  arterial hypertension, and tachycardia have been anecdotally 
reported following latanoprost use.92,93 In a randomized study, 
headache was more frequent in patients receiving latanoprost 
than in those receiving bimatoprost although this difference 
did not reach statistical significance.6 Patients with no prior 
history of migraine and/or headache have reported migraine 
after receiving latanoprost treatment.62
Bimatoprost is classified as a category C drug according to 
the use-in-pregnancy ratings of the FDA. Category C denotes 
that animal reproduction studies have shown an adverse effect 
on the fetus, with no adequate and well-controlled studies in 
humans. Potential benefits of the drug, however, may warrant 
its use in pregnant women despite potential risks. Experience 
of ophthalmic prostaglandin analogs and prostamide use 
during human pregnancy is limited. In an observation study 
of 10 pregnant women exposed to latanoprost during the 
first trimester, 9 women delivered normal fetuses with 
no malformations. One pregnancy was complicated by 
  miscarriage, which occurred 2 weeks after treatment was 
ended in a 46-year-old woman, primi-gravida, who had 
increased reproductive risk related to her advanced age.94
Conclusion
Latisse® is identical to Lumigan® with bimatoprost 0.03% 
as the active ingredient. Lumigan® is marketed for reduction 
of elevated IOP in patients with glaucoma, while Latisse® 
is approved for increasing eyelash length, thickness and 
darkness in patients with hypotrichosis of the eyelashes. For 
eyelash enhancement, 1 drop of bimatoprost 0.03% solution 
is placed on a single-use applicator and applied to the upper 
eyelid margin along the roots of the eyelashes once nightly; 
a new applicator should be used for each eye.
Bimatoprost is a synthetic prostaglandin analog. But unlike 
the prostaglandin F2α analogs such as latanoprost, travoprost 
and unoprostone, bimatoprost has an ethyl amide rather than 
an isopropyl ester at the C-1 carbon of the alpha chain, and 
can be classified as a prostamide. Prostaglandin or prostamide 
analogs are potent agents in the reduction of elevated IOP and 
hypertrichosis was found to be a regular side effect. This once 
perceived side effect is now a desirable outcome for patients Clinical Ophthalmology 2010:4
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who prefer to have longer, thicker, and darker eyelashes.2 
Clinical trial of bimatoprost for eyelash growth conducted by 
the manufacturer and other clinical trials using bimatoprost as 
a glaucoma therapy have shown that it is an effective agent 
in promoting eyelash growth. Bimatoprost most likely works 
by interacting with the prostaglandin receptors in the hair 
follicle and stimulating the resting follicles (telogen phase) 
to growing follicles (anagen phase). Although bimatoprost is 
effective in promoting increased growth of healthy eyelashes 
and adnexal hairs, its effectiveness in patients with eyelash 
alopecia areata is debatable and its protective effect is not yet 
studied in patients with eyelash loss secondary to radiation or 
chemotherapy. Apparently, an intact hair follicle is necessary 
for exogenous prostaglandin analogs to be effective in the 
promotion of hair growth.
Bimatoprost is generally safe when applied to the base 
of the eyelash at the lid margin with minimum side effects 
including ocular or lid irritation, conjunctiva hyperemia and 
hyperpigmentaton of the lid. Other ocular or systemic side 
effects associated with ophthalmic bimatoprost and other 
prostaglandin analogs when instilled on the surface of the eye 
should be monitored, and patients must be informed.
Based on the general desire of longer, thicker, and darker 
eyelashes as a sign of femininity and beauty in most cultures, 
and the high volume of mascara sales, Latisse® is expected 
to be a popular alternative for those seeking to augment their 
lash appearance.
Disclosure
The author has received honoraria from Allergan Inc.
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